Sign In
Buy MIRM
$105.95
-6.64 (-5.90%)
At Close: Jul 31, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:30pm, Thursday, 12'th Mar 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of “Moderate Buy” by Brokerages
04:33am, Tuesday, 10'th Mar 2026
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen analysts that are covering the company, MarketBeat Ratings repo
Mirum Completes Enrollment & Screening in Liver Disease Studies
09:30am, Friday, 06'th Mar 2026
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
08:00am, Thursday, 05'th Mar 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus.
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
11:51am, Thursday, 26'th Feb 2026
MIRM posts Q4 loss. Revenues jump 50% on strong Livmarli and bile acid drug sales, topping estimates in Q4 2025 and lifting shares.
Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
09:01pm, Wednesday, 25'th Feb 2026
Although the revenue and EPS for Mirum Pharmaceuticals (MIRM) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
08:25pm, Wednesday, 25'th Feb 2026
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.49 per share a year ago.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
06:37pm, Wednesday, 25'th Feb 2026
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
04:01pm, Wednesday, 25'th Feb 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
04:01pm, Monday, 23'rd Feb 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
GSA Capital Partners LLP Sells 18,800 Shares of Mirum Pharmaceuticals, Inc. $MIRM
05:52am, Monday, 23'rd Feb 2026
GSA Capital Partners LLP reduced its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) by 69.5% during the third quarter, according to its most recent Form 13F filing with the Securities a
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
04:01pm, Wednesday, 18'th Feb 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026.
Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release
11:05am, Wednesday, 18'th Feb 2026
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10:45pm, Tuesday, 10'th Feb 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
